Cytosorbents Corporation
CTSO
$0.79
$0.045.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.12% | 8.76% | -2.92% | 91.64% | -2.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.12% | 8.76% | -2.92% | 91.64% | -2.24% |
| Cost of Revenue | -16.03% | 19.84% | 19.08% | 83.12% | 4.78% |
| Gross Profit | 26.83% | 4.78% | -9.69% | 38.97% | -6.26% |
| SG&A Expenses | 3.06% | 7.17% | -9.17% | -14.25% | -9.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.96% | 6.61% | -7.56% | -22.05% | -16.49% |
| Operating Income | 43.72% | -1.26% | 16.52% | 58.71% | 34.00% |
| Income Before Tax | -29.01% | 145.34% | 75.72% | -29.60% | 69.89% |
| Income Tax Expenses | -- | -- | -- | -107.79% | -- |
| Earnings from Continuing Operations | -14.52% | 145.34% | 75.72% | -19.92% | 69.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.52% | 145.34% | 75.72% | -19.92% | 69.89% |
| EBIT | 43.72% | -1.26% | 16.52% | 58.71% | 34.00% |
| EBITDA | 47.14% | -1.30% | 17.38% | 60.95% | 35.70% |
| EPS Basic | 0.59% | 139.32% | 78.28% | -2.05% | 75.48% |
| Normalized Basic EPS | -9.80% | 139.27% | 78.25% | -7.01% | 75.89% |
| EPS Diluted | 0.59% | 137.50% | 78.28% | -2.05% | 75.48% |
| Normalized Diluted EPS | -9.80% | 136.64% | 78.25% | -7.01% | 75.89% |
| Average Basic Shares Outstanding | 15.24% | 15.29% | 11.57% | 17.53% | 22.71% |
| Average Diluted Shares Outstanding | 15.24% | 23.68% | 11.57% | 17.53% | 22.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |